Can-Fite BioPharma (NYSE:CANF) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a report released on Friday. The firm issued a sell rating on the stock.

A number of other brokerages have also weighed in on CANF. HC Wainwright restated a “buy” rating and set a $18.00 price objective on shares of Can-Fite BioPharma in a research report on Tuesday, November 12th. D. Boral Capital restated a “buy” rating and set a $10.00 price objective on shares of Can-Fite BioPharma in a research report on Monday, March 3rd.

Can-Fite BioPharma Stock Performance

Shares of CANF stock opened at $1.58 on Friday. Can-Fite BioPharma has a 52-week low of $1.29 and a 52-week high of $4.69. The firm has a market capitalization of $5.59 million, a PE ratio of -0.88 and a beta of 1.12. The stock has a fifty day simple moving average of $1.59 and a two-hundred day simple moving average of $1.91.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Rhumbline Advisers raised its holdings in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) by 58.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 26,880 shares of the company’s stock after buying an additional 9,935 shares during the period. Rhumbline Advisers owned about 0.76% of Can-Fite BioPharma worth $44,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 21.00% of the company’s stock.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.